615253-61-7
| 中文名称 | 615253-61-7 |
|---|---|
| 中文同义词 | 化合物 T16914 |
| 英文名称 | SP187 |
| 英文同义词 | SP187;3,4,5-Piperidinetriol, 2-(hydroxymethyl)-1-(9-methoxynonyl)-, (2R,3R,4R,5S)-;UV-4B;MON-?DNJ;UV4);SP187 (MON-?DNJ;SP-187,SP187 |
| CAS号 | 615253-61-7 |
| 分子式 | C16H33NO5 |
| 分子量 | 319.44 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 615253-61-7.mol |
| 结构式 |  |
615253-61-7 性质
| 沸点 | 475.0±40.0 °C(Predicted) |
|---|---|
| 密度 | 1.128±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 13.72±0.70(Predicted) |
IC50: 29.97 μM (EBOV), 47.72 μM (MARV)
The antiviral activity of iminosugar SP187 (UV-4) in vitro against EBOV and MARV is assessed using a yield-plaque assay format and the IC 50 is determined. Antiviral activity for SP187 is observed with IC 50 of 29.97 and 47.72 μM for EBOV and MARV, respectively.
The efficacy of SP187 (UV-4), the active free base component of UV-4B, and UV-5, the most potent iminosugar tested in vitro, is first assessed using a mouse model of EBOV infection. In this study, C57Bl/6 mice are administered 10 or 100 mg/kg of SP187 or UV-5 via oral gavage or IP injection. Dosing started ~1h before infection with ~1000 pfu of mouse-adapted EBOV and is repeated BID for 10 days at approximately 12 hour intervals for UV-5 or TID at approximately 8 hour intervals for SP187. The selected doses and schedule are based on tolerability studies in naïve mice. No efficacy is observed in the iminosugar treated mice as compared to the vehicle control.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-U00160 | 615253-61-7 SP187 | 615253-61-7 | 5mg | 6000元 |
| 2024/04/30 | HY-U00160 | 615253-61-7 SP187 | 10 mM * 1 mLin DMSO | 6600元 |